Similar companies
Income Statement (USD)
| Q1 '24 | QoQ | |
|---|---|---|
| Revenue | 19M | 137.1% |
| Gross Profit | -7.3M | 305.5% |
| Cost of Revenue | 26M | 168.5% |
| Operating expense | 87M | 18.3% |
| Net Income | -70M | 21.1% |
| EBITDA | -49M | 13.6% |
Balance Sheet (USD)
| Q1 '24 | QoQ | |
|---|---|---|
| Total Assets | 631M | 2% |
| Total Liabilities | 500M | 17.9% |
| Total Equity | 131M | 32.6% |
| Shares Outstanding | 194M | 0.4% |
Cash Flow (USD)
| Q1 '24 | QoQ | |
|---|---|---|
| Cash from operations | -75M | 441.3% |
| Cash from investing | -660,000 | 117.3% |
| Cash from financing | 65M | 2.5% |
EPS
Financial Highlights for Bluebird bio in Q1 '24
Bluebird bio reported a revenue of 19M, which is a 137.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -7.3M, marking a -305.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 26M, a 168.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 87M, showing a -18.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -70M, showing a 21.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -49M, showing a 13.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Bluebird bio faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
